GlassScriptPhysician profile
Karl Jay Barton
NPI 1306889522
$806.40
in general payments reported to CMS, 2019-2025
15 companies · $293 in 2025
The $293 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $178 · 2022: $88.16 · 2023: $91.26 · 2024: $155 · 2025: $293.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $532 · Education: $7.52.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $532.29 |
| Education | $7.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Supernus Pharmaceuticals, INC. | $188.13 | 2022-2025 | Qelbree |
| Abbvie INC. | $165.51 | 2021-2025 | |
| Amgen INC. | $97.98 | 2022-2024 | Otezla, Repatha |
| Sunovion Pharmaceuticals INC. | $76.11 | 2021 | |
| Axsome Therapeutics, INC. | $51.85 | 2023-2025 | Auvelity |
| Inspire Medical Systems, INC. | $45.85 | 2023-2025 | Inspire |
| Novo Nordisk INC | $35.15 | 2021-2023 | Wegovy |
| Vertex Pharmaceuticals Incorporated | $26.13 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $21.67 | 2024 | Caplyta |
| Boston Scientific Corporation | $19.46 | 2024 | Varithena Administration Pack |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.06 | 2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.25 | 2021 | |
| Abbott Laboratories | $16.05 | 2021 | |
| Lilly USA, LLC | $15.53 | 2021 | |
| Genentech USA, INC. | $11.67 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karl Barton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.